bluebird bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$484M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • bluebird bio's estimated annual revenue is currently $53.6M per year.(i)
  • bluebird bio received $632.5M in venture funding in July 2018.
  • bluebird bio's estimated revenue per employee is $71,343
  • bluebird bio's total funding is $484M.
  • bluebird bio's current valuation is $612M. (January 2022)

Employee Data

  • bluebird bio has 752 Employees.(i)
  • bluebird bio grew their employee count by -50% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$484M

Total Funding

752

Number of Employees

$53.6M

Revenue (est)

-50%

Employee Growth %

$612M

Valuation

N/A

Accelerator

bluebird bio News

2022-04-20 - Bluebird bio's gene therapy Zynteglo could have high price ...

Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...

2022-04-17 - Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash

Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...

2022-03-30 - Bluebird bio cuts 30% of its workforce as gene therapy dreams ...

The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...

2021-09-08 - bluebird bio : Secures $75 Million in Private Placement Equity Financing

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...

2021-06-07 - BLUEBIRD BIO, INC. Bluebird bio : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies (Form 8-K)

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$97.7M75247%$1.1B
#2
$156.3M75436%$90M
#3
$215.2M76121%N/A
#4
$138.7M7621%N/A
#5
$295.6M7822%N/A

bluebird bio Funding

DateAmountRoundLead InvestorsReference
2011-04-21$30.0MUndisclosedARCH Venture Partners, Third Rock VenturesArticle
2012-07-26$60.0MDDeerfield Partners, RA CapitalArticle
2013-06-03$60.0MDDeerfield Partners, RA CapitalArticle
2014-12-17$150.0MUndisclosedArticle
2015-06-25$575.0MBofA Merrill LynchArticle
2016-12-08$200.0MUndisclosedGoldman, Sachs & CoArticle
2017-06-28$350.0MUndisclosedGoldman Sachs & Co. LLCArticle
2017-12-14$600.0MUndisclosedMultipleArticle
2018-01-10$651.3MUndisclosedMultipleArticle
2018-07-25$632.5MUndisclosedMultipleArticle